Leptin as an adjunct of insulin therapy in insulin-deficient diabetes

F. Miyanaga, Y. Ogawa, K. Ebihara, S. Hidaka, T. Tanaka, S. Hayashi, H. Masuzaki, K. Nakao

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Aims/hypothesis. The purpose of this study was to assess the therapeutic implication of leptin in insulin-deficient diabetes. Methods. Insulin-deficient diabetes was induced by streptozotocin (STZ) in transgenic skinny mice overexpressing leptin. Plasma concentrations of glucose, insulin, and leptin were measured. The effects on body weight, food intake, and hypothalamic gene expressions were analyzed. After diabetes was induced, graded doses of insulin ranging from 0.4 to 51.2 mU·g-1·day-1 were injected. Co-administration of leptin and insulin was also carried out using osmotic pumps. Results. After STZ injection, both transgenic and nontransgenic littermates developed marked hyperglycaemia as a result of severe hypoinsulinaemia [termed diabetic transgenic skinny mice overexpressing leptin (diabetic TGM) and diabetic non-transgenic littermates (diabetic WT) respectively], although diabetic TGM were more sensitive to exogenously administered insulin than diabetic WT. Diabetic WT were hypoleptinaemic and hyperphagic relative to non-diabetic WT, whereas diabetic TGM, which remained hyperleptinaemic, were less hyperphagic than diabetic WT. After STZ injection, hypothalamic expressions of orexigenic and anorexigenic peptide mRNAs were upregulated and down-regulated, respectively, in diabetic WT, whereas they were unchanged in diabetic TGM. Diabetic TGM became normoglycaemic, when treated with insulin at such doses that did not improve hyperglycaemia in diabetic WT. We found that a subthreshold dose of insulin that does not affect glucose homeostasis is effective in improving the diabetes in normal mice rendered diabetic by STZ injection, when combined with leptin. Conclusions/ interpretation. This study suggests that leptin could be used as an adjunct of insulin therapy in insulin-deficient diabetes, thereby providing an insight into the therapeutic implication of leptin as an anti-diabetic agent.

Original languageEnglish
Pages (from-to)1329-1337
Number of pages9
JournalDiabetologia
Volume46
Issue number10
DOIs
Publication statusPublished - Oct 1 2003
Externally publishedYes

Fingerprint

Leptin
Insulin
Transgenic Mice
Streptozocin
Therapeutics
Hyperglycemia
Injections
Glucose
Homeostasis
Eating
Body Weight
Gene Expression
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Miyanaga, F., Ogawa, Y., Ebihara, K., Hidaka, S., Tanaka, T., Hayashi, S., ... Nakao, K. (2003). Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. Diabetologia, 46(10), 1329-1337. https://doi.org/10.1007/s00125-003-1193-6

Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. / Miyanaga, F.; Ogawa, Y.; Ebihara, K.; Hidaka, S.; Tanaka, T.; Hayashi, S.; Masuzaki, H.; Nakao, K.

In: Diabetologia, Vol. 46, No. 10, 01.10.2003, p. 1329-1337.

Research output: Contribution to journalArticle

Miyanaga, F, Ogawa, Y, Ebihara, K, Hidaka, S, Tanaka, T, Hayashi, S, Masuzaki, H & Nakao, K 2003, 'Leptin as an adjunct of insulin therapy in insulin-deficient diabetes', Diabetologia, vol. 46, no. 10, pp. 1329-1337. https://doi.org/10.1007/s00125-003-1193-6
Miyanaga F, Ogawa Y, Ebihara K, Hidaka S, Tanaka T, Hayashi S et al. Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. Diabetologia. 2003 Oct 1;46(10):1329-1337. https://doi.org/10.1007/s00125-003-1193-6
Miyanaga, F. ; Ogawa, Y. ; Ebihara, K. ; Hidaka, S. ; Tanaka, T. ; Hayashi, S. ; Masuzaki, H. ; Nakao, K. / Leptin as an adjunct of insulin therapy in insulin-deficient diabetes. In: Diabetologia. 2003 ; Vol. 46, No. 10. pp. 1329-1337.
@article{d5bbc83bf17d44b6999572dabd0183a1,
title = "Leptin as an adjunct of insulin therapy in insulin-deficient diabetes",
abstract = "Aims/hypothesis. The purpose of this study was to assess the therapeutic implication of leptin in insulin-deficient diabetes. Methods. Insulin-deficient diabetes was induced by streptozotocin (STZ) in transgenic skinny mice overexpressing leptin. Plasma concentrations of glucose, insulin, and leptin were measured. The effects on body weight, food intake, and hypothalamic gene expressions were analyzed. After diabetes was induced, graded doses of insulin ranging from 0.4 to 51.2 mU·g-1·day-1 were injected. Co-administration of leptin and insulin was also carried out using osmotic pumps. Results. After STZ injection, both transgenic and nontransgenic littermates developed marked hyperglycaemia as a result of severe hypoinsulinaemia [termed diabetic transgenic skinny mice overexpressing leptin (diabetic TGM) and diabetic non-transgenic littermates (diabetic WT) respectively], although diabetic TGM were more sensitive to exogenously administered insulin than diabetic WT. Diabetic WT were hypoleptinaemic and hyperphagic relative to non-diabetic WT, whereas diabetic TGM, which remained hyperleptinaemic, were less hyperphagic than diabetic WT. After STZ injection, hypothalamic expressions of orexigenic and anorexigenic peptide mRNAs were upregulated and down-regulated, respectively, in diabetic WT, whereas they were unchanged in diabetic TGM. Diabetic TGM became normoglycaemic, when treated with insulin at such doses that did not improve hyperglycaemia in diabetic WT. We found that a subthreshold dose of insulin that does not affect glucose homeostasis is effective in improving the diabetes in normal mice rendered diabetic by STZ injection, when combined with leptin. Conclusions/ interpretation. This study suggests that leptin could be used as an adjunct of insulin therapy in insulin-deficient diabetes, thereby providing an insight into the therapeutic implication of leptin as an anti-diabetic agent.",
author = "F. Miyanaga and Y. Ogawa and K. Ebihara and S. Hidaka and T. Tanaka and S. Hayashi and H. Masuzaki and K. Nakao",
year = "2003",
month = "10",
day = "1",
doi = "10.1007/s00125-003-1193-6",
language = "English",
volume = "46",
pages = "1329--1337",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",
number = "10",

}

TY - JOUR

T1 - Leptin as an adjunct of insulin therapy in insulin-deficient diabetes

AU - Miyanaga, F.

AU - Ogawa, Y.

AU - Ebihara, K.

AU - Hidaka, S.

AU - Tanaka, T.

AU - Hayashi, S.

AU - Masuzaki, H.

AU - Nakao, K.

PY - 2003/10/1

Y1 - 2003/10/1

N2 - Aims/hypothesis. The purpose of this study was to assess the therapeutic implication of leptin in insulin-deficient diabetes. Methods. Insulin-deficient diabetes was induced by streptozotocin (STZ) in transgenic skinny mice overexpressing leptin. Plasma concentrations of glucose, insulin, and leptin were measured. The effects on body weight, food intake, and hypothalamic gene expressions were analyzed. After diabetes was induced, graded doses of insulin ranging from 0.4 to 51.2 mU·g-1·day-1 were injected. Co-administration of leptin and insulin was also carried out using osmotic pumps. Results. After STZ injection, both transgenic and nontransgenic littermates developed marked hyperglycaemia as a result of severe hypoinsulinaemia [termed diabetic transgenic skinny mice overexpressing leptin (diabetic TGM) and diabetic non-transgenic littermates (diabetic WT) respectively], although diabetic TGM were more sensitive to exogenously administered insulin than diabetic WT. Diabetic WT were hypoleptinaemic and hyperphagic relative to non-diabetic WT, whereas diabetic TGM, which remained hyperleptinaemic, were less hyperphagic than diabetic WT. After STZ injection, hypothalamic expressions of orexigenic and anorexigenic peptide mRNAs were upregulated and down-regulated, respectively, in diabetic WT, whereas they were unchanged in diabetic TGM. Diabetic TGM became normoglycaemic, when treated with insulin at such doses that did not improve hyperglycaemia in diabetic WT. We found that a subthreshold dose of insulin that does not affect glucose homeostasis is effective in improving the diabetes in normal mice rendered diabetic by STZ injection, when combined with leptin. Conclusions/ interpretation. This study suggests that leptin could be used as an adjunct of insulin therapy in insulin-deficient diabetes, thereby providing an insight into the therapeutic implication of leptin as an anti-diabetic agent.

AB - Aims/hypothesis. The purpose of this study was to assess the therapeutic implication of leptin in insulin-deficient diabetes. Methods. Insulin-deficient diabetes was induced by streptozotocin (STZ) in transgenic skinny mice overexpressing leptin. Plasma concentrations of glucose, insulin, and leptin were measured. The effects on body weight, food intake, and hypothalamic gene expressions were analyzed. After diabetes was induced, graded doses of insulin ranging from 0.4 to 51.2 mU·g-1·day-1 were injected. Co-administration of leptin and insulin was also carried out using osmotic pumps. Results. After STZ injection, both transgenic and nontransgenic littermates developed marked hyperglycaemia as a result of severe hypoinsulinaemia [termed diabetic transgenic skinny mice overexpressing leptin (diabetic TGM) and diabetic non-transgenic littermates (diabetic WT) respectively], although diabetic TGM were more sensitive to exogenously administered insulin than diabetic WT. Diabetic WT were hypoleptinaemic and hyperphagic relative to non-diabetic WT, whereas diabetic TGM, which remained hyperleptinaemic, were less hyperphagic than diabetic WT. After STZ injection, hypothalamic expressions of orexigenic and anorexigenic peptide mRNAs were upregulated and down-regulated, respectively, in diabetic WT, whereas they were unchanged in diabetic TGM. Diabetic TGM became normoglycaemic, when treated with insulin at such doses that did not improve hyperglycaemia in diabetic WT. We found that a subthreshold dose of insulin that does not affect glucose homeostasis is effective in improving the diabetes in normal mice rendered diabetic by STZ injection, when combined with leptin. Conclusions/ interpretation. This study suggests that leptin could be used as an adjunct of insulin therapy in insulin-deficient diabetes, thereby providing an insight into the therapeutic implication of leptin as an anti-diabetic agent.

UR - http://www.scopus.com/inward/record.url?scp=0142029960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0142029960&partnerID=8YFLogxK

U2 - 10.1007/s00125-003-1193-6

DO - 10.1007/s00125-003-1193-6

M3 - Article

C2 - 12928770

AN - SCOPUS:0142029960

VL - 46

SP - 1329

EP - 1337

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 10

ER -